Drug Development: Protease Inhibitors: A Tale of Two Companies

+ See all authors and affiliations

Science  28 Jun 1996:
Vol. 272, Issue 5270, pp. 1882-1883
DOI: 10.1126/science.272.5270.1882

You are currently viewing the summary.

View Full Text


A new class of anti-HIV drugs called protease inhibitors offers the most promising therapy so far. In combination with other antiviral drugs, they can reduce virus loads to undetectable levels. The manufacturers of the two leading protease inhibitors, Merck and Abbott, took different routes but arrived at the finishing post at almost exactly the same time.